We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Guillain-Barr Syndrome Caused by Cytomegalovirus after Multiple Myeloma Treatment.
- Authors
Cancan Lu; Huixian Hu; Yishan Ye; Zhen Cai
- Abstract
Background: Both humoral and cell-mediated immunity of the patient affected by multiple myeloma (MM) are impaired; thus, infection is the main cause of the onset of symptoms and death caused by MM. Bortezomib is a first-line drug approved for patients with multiple myeloma (MM) and has significantly increased their overall survival. However, bortezomib-induced peripheral neuropathy (PN) remains a significant side effect that has led to its discontinuation in some patients. Guillain-Barre syndrome (GBS) is thought to be related to immune damage, and most patients have cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma infection before onset. Cases of GBS secondary to MM are rare. Methods: We provide a case of GBS caused by cytomegalovirus infection after MM treatment, and briefly review the existing literature. Results: Secondary GBS after MM. This patient received active treatment. The clinical symptoms are gradually improving. Conclusions: The use of bortezomib has the risk of reactivating the virus. It is more about the reactivation of hepatitis B virus. Nonetheless, cytomegalovirus and Epstein-Barr virus shall have our attention. Patients with MM need to monitor CMV, regularly, especially during the treatment of bortezomib. At the same time, they also need to closely monitor the symptoms and signs of the nervous system to guard against the occurrence of GBS.
- Subjects
EPSTEIN-Barr virus; CYTOMEGALOVIRUSES; MULTIPLE myeloma; GUILLAIN-Barre syndrome; HEPATITIS B virus; CYTOMEGALOVIRUS diseases; SYMPTOMS
- Publication
Clinical Laboratory, 2024, Vol 70, Issue 6, p1175
- ISSN
1433-6510
- Publication type
Article
- DOI
10.7754/Clin.Lab.2024.231224